BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that SGN-35 has been granted orphan drug designation by the European Medicines Agency (EMEA) for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) and by the U.S. Food and Drug Administration (FDA) for the treatment of ALCL. These designations are in addition to the SGN-35 orphan drug designation for Hodgkin lymphoma previously received from the FDA. The company plans to initiate a pivotal trial of SGN-35 for Hodgkin lymphoma and a phase II clinical trial for ALCL during the first quarter of 2009.
